Gyeongsang National University Hospital
Jinju 660-702
4 studies enrolling now · 14 studies all time
What they study most
Advanced Cholangiocarcinoma, Advanced Solid Tumors, Atrial Fibrillation, Carcinoma, Non-Small-Cell Lung, FGFR2 Fusions, Gastric Cancer, Gastro-Oesophageal Cancer, Gastroesophageal-junction Cancer, Gene Rearrangement, HER2-amplified Biliary Tract Cancers, HER2-positive Gastric Cancer, HNSCC
Studies at this site
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
- Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement — Recruiting now
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer — Recruiting now
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer — Recruiting now
- To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation — Recruiting now
- RegoNivo vs Standard of Care Chemotherapy in AGOC — Completed
- Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) — Running, not enrolling
- Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC — Stopped early
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Running, not enrolling
- A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers — Completed
- Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis — Stopped early
- A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer — Status unconfirmed
- GLORIA-AF Registry Program - Second and Third Phases — Completed
- LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy — Completed